HER2-enriched subtype is a predictor of complete response following neoadjuvant therapy with dual HER2 inhibitors (trastuzumab and lapatinib) without chemotherapy in early stage HER2-positive breast cancer [88]. Here, ERBB2 is linked to breast carcinoma.